RLAY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Relay Therapeutics Inc (RLAY) does not currently present a strong buy opportunity for a beginner, long-term investor with $50,000-$100,000 available for investment. The technical indicators are neutral, there are no significant positive catalysts in the news or congress trading data, and the financial performance shows declining net income and EPS. While hedge funds are buying, the overall sentiment and lack of strong trading signals suggest holding off on purchasing at this time.
The MACD histogram is negative (-0.112), indicating bearish momentum, but it is contracting, which suggests potential stabilization. RSI is neutral at 57.809, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level (10.237), with support at 9.387 and resistance at 11.087.
Hedge funds are significantly increasing their positions, with a 352.49% increase in buying over the last quarter. Analysts have raised price targets recently, with targets ranging from $14 to $22, and the company is progressing in its Phase 3 trials with promising data.
The pre-market price is down by -1.98%, reflecting negative sentiment. No recent news or congress trading data is available. Financial performance shows a decline in net income (-27.78% YoY) and EPS (-28.89% YoY), with no revenue growth.
In 2025/Q4, revenue remained flat at $7 million YoY. Net income dropped to -$54.89 million (-27.78% YoY), and EPS declined to -0.32 (-28.89% YoY). Gross margin remained at 100%, but the lack of profitability and growth is concerning.
Analysts are optimistic, with multiple firms raising price targets recently. H.C. Wainwright raised the target to $19, Citizens to $17, and Guggenheim to $22, all maintaining Buy or Outperform ratings. Analysts are confident in the company's drug pipeline and ongoing trials, but the financials and market sentiment do not currently align with these ratings.
